Co-stimulation with LPS or Poly I:C markedly enhances the anti-platelet immune response and severity of fetal and neonatal alloimmune thrombocytopenia

Summary

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a life-threatening bleeding disorder caused by maternal antibodies against fetal/neonatal platelets. FNAIT is also linked with miscarriages, although the incidence and mechanisms of fetal death have not been well studied. Integrin αIIbβ3 (GPIIbIIIa) and the GPIbα complex are major glycoproteins expressed on platelets and are also major antigens targeted in autoimmune thrombocytopenia (ITP), but reported cases of anti-GPIb-mediated FNAIT are rare. Bacterial and viral infections have been causally linked with the pathogenesis of immune-mediated thrombocytopenia (ITP); however, it is unknown whether these infections contribute to the severity of FNAIT. Here, immune responses against platelet antigens were examined by transfusing wild-type (WT) mouse platelets into β3^-/- or GPIbα^-/- mice. To mimic bacterial or viral infections, lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (Poly I:C) were injected intraperitoneally following platelet transfusions. The FNAIT model was established by breeding the immunised female mice with WT male mice. We demonstrated for the first time that the platelet GPIbα has lower immunogenicity compared to β3 integrin. Interestingly, co-stimulation with LPS or Poly I:C markedly enhanced the immune response against platelet GPIbα and caused severe pathology of FNAIT (i.e. miscarriages). LPS or Poly I:C also enhanced the immune response against platelet β3 integrin. Our data suggest that bacterial and viral infections facilitate the anti-platelet GPIbα response, which may lead to a severe non-classical FNAIT (i.e. miscarriage but not neonatal bleeding) that has not been adequately reported in humans.

Keywords

Alloimmune thrombocytopenia - platelets - β3 integrin - GPIbα - infection

• References

• 1 Bussel JB, Zabusky MR, Berkowitz RL. et al. Fetal alloimmune thrombocytopenia. N Engl J Med 1997; 337: 22-26.
• 2 Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev 2008; 22: 33-52.
• 3 Kaplan C. Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis 2006; 1: 39.
• 4 Bertrand G, Drame M, Martageix C. et al. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood 2011; 117: 3209-3213.
• 5 Mueller-Eckhardt C, Kiefel V, Grubert A. et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989; 1: 363-366.
• 6 Turner ML, Bessos H, Fagge T. et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005; 45: 1945-1956.
• 7 Killie MK, Husebekk A, Kjeldsen-Kragh J. et al. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn. Haematologica 2008; 93: 870-877.
• 8 Williamson LM, Hackett G, Rennie J. et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998; 92: 2280-2287.
• 9 Murphy MF, Hambley H, Nicolaides K. et al. Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn 1996; 16: 1152-1155.
• 10 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
• 11 Wang Y, Andrews M, Yang Y. et al. Platelets in thrombosis and hemostasis: old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets 2012; 12: 126-132.
• 12 Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991; 65: 359-362.
• 13 Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: 611-616.
• 14 Modderman PW, Admiraal LG, Sonnenberg A. et al. Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. J Biol Chem 1992; 267: 364-369.
• 15 Wagner CL, Mascelli MA, Neblock DS. et al. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-914.
• 16 Li C, Piran S, Chen P. et al. The maternal immune response to fetal platelet GPIbalpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011; 121: 4537-4547.
• 17 Tong MH, Jiang H, Liu P. et al. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med 2005; 11: 153-159.
• 18 Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol 2007; 14: 535-556.
• 19 Cines DB, Bussel JB, Liebman HA. et al. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511-6521.
• 20 Gasbarrini A, Franceschi F, Tartaglione R. et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352: 878.
• 21 Michel M, Cooper N, Jean C. et al. Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?. Blood 2004; 103: 890-896.
• 22 Chen P, Li C, Lang S. et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010; 116: 3660-3668.
• 23 Kroll H, Kiefel V, Santoso S. Clinical aspects and typing of platelet alloantigens. Vox Sang 1998; 74 (Suppl. 02) 345-354.
• 24 McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am 2009; 23: 1163-1175.
• 25 Bizzaro N, Dianese G. Neonatal alloimmune amegakaryocytosis. Case report. Vox Sang 1988; 54: 112-114.
• 26 Goldman M, Trudel E, Richard L. et al. Neonatal alloimmune thrombocytopenia due to anti-HPA-2b (anti-Koa). Immunohematology 2003; 19: 43-46.
• 27 Kiefel V, Vicariot M, Giovangrandi Y. et al. Alloimmunization against Iy, a low-frequency antigen on platelet glycoprotein Ib/IX as a cause of severe neonatal alloimmune thrombocytopenic purpura. Vox Sang 1995; 69: 250-254.
• 28 Hodivala-Dilke KM, McHugh KP, Tsakiris DA. et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-238.
• 29 Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci USA 2000; 97: 2803-2808.
• 30 Yang H, Lang S, Zhai Z. et al. Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood 2009; 114: 425-436.
• 31 Aslam R, Speck ER, Kim M. et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107: 637-641.
• 32 Gustot T, Lemmers A, Moreno C. et al. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006; 43: 989-1000.
• 33 Lin AC, Dissanayake D, Dhanji S. et al. Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity. PLoS One 2011; 6: e23940.
• 34 Ni H, Chen P, Spring CM. et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006; 107: 2976-2983.
• 35 Tiller H, Killie MK, Chen P. et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion 2012; 52: 1446-1457.
• 36 Shivdasani RA, Rosenblatt MF, Zucker-Franklin D. et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995; 81: 695-704.
• 37 Choavaratana R, Uer-Areewong S, Makanantakosol S. Feto-maternal transfusion in normal pregnancy and during delivery. J Med Assoc Thai 1997; 80: 96-100.
• 38 Lens D, Brugnini A, Trías N. et al. Association between recurrent pregnancy loss and prothrombotic gene polymorphisms. J Thromb Haemost 2003; 1: P0951.
• 39 Fujimori K, Ohto H, Honda S. et al. Antepartum diagnosis of fetal intracranial hemorrhage due to maternal Bernard-Soulier syndrome. Obstet Gynecol 1999; 94: 817-819.
• 40 Peitsidis P, Datta T, Pafilis I. et al. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010; 16: 584-591.
• 41 Hickstein H, Barz D, Kulz T. et al. Protein A immunoadsorption in a pregnant woman with habitual abortion. Transfus Apher Sci 2002; 27: 259-261.
• 42 Aledort LM, Hayward CP, Chen MG. et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76: 205-213.
• 43 Grohmann U, Belladonna ML, Bianchi R. et al. Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex. Cancer Immunol Immunother 1999; 48: 195-203.
• 44 Freire T, Lo-Man R, Bay S. et al. Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem 2011; 286: 7797-7811.
• 45 Uff S, Clemetson JM, Harrison T. et al. Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation. J Biol Chem 2002; 277: 35657-35663.
• 46 Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89.
• 47 Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008; 8: 607-618.
• 48 Tsujimoto H, Efron PA, Matsumoto T. et al. Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA. Immunol Lett 2006; 107: 155-162.
• 49 Hertz CJ, Kiertscher SM, Godowski PJ. et al. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 2001; 166: 2444-2450.
• 50 Kjeldsen-Kragh J, Killie MK, Tomter G. et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110: 833-839.